NorDiag adds an additional potential revenue source in areas outside of N. America. The U.S. will remain the main source of revenue for EXAS over the next few years, as reimbursement is much more difficult overseas. The EXAS patent portfolio is much stronger in the U.S. and includes the broad use of stool DNA diagnosis in all cancers. We are days away from lift off!
Figured there was something going on behind the scenes. With mkt being all red rite now hard to judge what investors reactions will be. I would think positive myself because of worldwide exposure. I'm buying more.
Why license one of your bio-markers to another firm to use in the development of their own CRC test (international use only), when you have your own test, using multiple markers, that could be rolled out very soon? Seems a bit odd.